Hims & Hers Expands to Canada with Weight Loss Focus
US telehealth giant Hims & Hers enters Canadian market through Livewell acquisition, targeting obesity crisis with affordable digital healthcare and upcoming generic semaglutide access.
NOTRELOAD AI
Goldman Sachs Downgrades Halozyme to Sell
HALO faces a post-2030 royalty cliff; Goldman Sachs cuts rating to Sell with $56 target, citing long-term revenue risks.
Goldman Sachs Initiates Sell Rating on MBX Biosciences
Goldman Sachs starts coverage of MBX Biosciences with a Sell rating and $18 price target, citing cautious outlook ahead of key trial data in 2026.
Needham Starts Coverage on Solid Biosciences with Buy Rating
Needham initiates Buy on Solid Biosciences with $16 target, highlighting potential of SGT-003 gene therapy amid concerns over Sarepta’s Elevidys safety.
Five Below Soars on Strong Q3 Results, Raises Full-Year Outlook for Third Time
Five Below (FIVE) raises 2025 guidance after Q3 comparable sales jump 14.3%, signaling strong demand for affordable trendy products among budget-conscious shoppers.
Dollar General Raises 2025 Outlook as Budget Shoppers Boost Sales
Dollar General increases full-year profit forecast to $6.30-$6.50 per share after strong Q3 performance, benefiting from consumers seeking value amid economic uncertainty.